Blood-based biomarkers of adverse perinatal outcomes in maternal obesity

Abstract Objective: Increasing maternal weight has been shown to predict adverse perinatal outcome, including increases in the relative risk of fetal death, stillbirth, neonatal death, perinatal death and infant death. In order to better understand the pathophysiological factors associated with obesity during pregnancy, the role of biomarkers associated with adverse outcomes in obese pregnant women is under investigation. The purpose of this review study was to examine potential biomarkers that could serve as effective screening strategies in obese pregnant women to reduce fetal and neonatal morbidity, as well as maternal morbidity. Methods: Electronic databases (Pubmed, Embase) were searched for previously published research studies that investigated biomarkers associated with perinatal outcomes in obese pregnant women and the putative mechanisms underlying biomarker effects on pregnancy outcomes. Results: It is evident that while several biomarkers predict perinatal complications in obese pregnant women, none fulfilled the criteria to be considered clinically useful. Conclusion: There is a critical need for reliable blood-based biomarkers associated with an increased risk of adverse perinatal outcomes in obese pregnant women.

[1]  M. M. Rahman,et al.  Worldwide trends in diabetes since 1980 : pooled analysis of 751 population-based measurement studies with over 4 . 4 million participants , 2016 .

[2]  A. Staff,et al.  Angiogenic biomarkers in pregnancy: defining maternal and fetal health , 2015, Acta obstetricia et gynecologica Scandinavica.

[3]  Simin Liu,et al.  Adipokine levels during the first or early second trimester of pregnancy and subsequent risk of gestational diabetes mellitus: A systematic review. , 2015, Metabolism: clinical and experimental.

[4]  Madhulika B. Gupta.  The role and regulation of IGFBP-1 phosphorylation in fetal growth restriction , 2015, Journal of Cell Communication and Signaling.

[5]  C. Zera,et al.  The association of body mass index with serum angiogenic markers in normal and abnormal pregnancies. , 2014, American journal of obstetrics and gynecology.

[6]  M. Lappas.  Insulin-like growth factor-binding protein 1 and 7 concentrations are lower in obese pregnant women, women with gestational diabetes and their fetuses , 2014, Journal of Perinatology.

[7]  Kypros H. Nicolaides,et al.  Early Prediction of Preeclampsia , 2014, Obstetrics and gynecology international.

[8]  M. Vickers,et al.  Maternal Obesity, Inflammation, and Developmental Programming , 2014, BioMed research international.

[9]  S. Tonstad,et al.  Maternal body mass index and the risk of fetal death, stillbirth, and infant death: a systematic review and meta-analysis. , 2014, JAMA.

[10]  T. Powell,et al.  Adiponectin and IGFBP-1 in the development of gestational diabetes in obese mothers , 2014, BMJ Open Diabetes Research and Care.

[11]  A. Caughey,et al.  Obesity in Pregnancy: A Big Problem and Getting Bigger , 2013, Obstetrical & gynecological survey.

[12]  R. Evans,et al.  Mid‐pregnancy maternal leptin levels, birthweight for gestational age and preterm delivery , 2013, Clinical endocrinology.

[13]  T. Powell,et al.  Review: Adiponectin--the missing link between maternal adiposity, placental transport and fetal growth? , 2013, Placenta.

[14]  A. Gruslin,et al.  Role of leptin in pregnancy: consequences of maternal obesity. , 2013, Placenta.

[15]  V. K. Misra,et al.  The Influence of Overweight and Obesity on Maternal Soluble fms-Like Tyrosine Kinase 1 and Its Relationship With Leptin During Pregnancy , 2013, Reproductive Sciences.

[16]  S. Ghosh,et al.  Serum placental growth factor as a predictor of early onset preeclampsia in overweight/obese pregnant women. , 2013, Journal of the American Society of Hypertension : JASH.

[17]  M. Hivert,et al.  Lower Adiponectin Levels at First Trimester of Pregnancy Are Associated With Increased Insulin Resistance and Higher Risk of Developing Gestational Diabetes Mellitus , 2013, Diabetes Care.

[18]  V. K. Misra,et al.  Maternal Serum Leptin During Pregnancy and Infant Birth Weight: the Influence of Maternal Overweight and Obesity , 2012, Obesity.

[19]  E. Vicaut,et al.  Limited value of angiogenic factors in obese women. , 2012, Pregnancy hypertension.

[20]  E. Levy,et al.  Maternal and fetal IGF-I and IGF-II levels, fetal growth, and gestational diabetes. , 2012, The Journal of clinical endocrinology and metabolism.

[21]  Alan,et al.  The Hyperglycemia and Adverse Pregnancy Outcome Study Associations of GDM and obesity with pregnancy outcomes , 2012 .

[22]  S. Karumanchi,et al.  Midpregnancy levels of angiogenic markers in relation to maternal characteristics. , 2011, American journal of obstetrics and gynecology.

[23]  K. Nicolaides,et al.  Maternal Serum Adiponectin at 11–13 Weeks of Gestation in Preeclampsia , 2011, Fetal Diagnosis and Therapy.

[24]  R. Romero,et al.  Maternal serum adiponectin multimers in preeclampsia , 2009, Journal of perinatal medicine.

[25]  L. Poston,et al.  A prospective study of pregnancy outcome and biomarkers of oxidative stress in nulliparous obese women. , 2009, American journal of obstetrics and gynecology.

[26]  M. Christiansen,et al.  Leptin in first trimester pregnancy serum: no reduction associated with small-for-gestational-age infants. , 2009, Reproductive biomedicine online.

[27]  K. Nicolaides,et al.  Circulating levels of adiponectin and leptin at 23-25 weeks of pregnancy in women with impaired placentation and in those with established fetal growth restriction. , 2008, Clinical science.

[28]  F. Corrado,et al.  Endoglin, PlGF and sFlt‐1 as markers for predicting pre‐eclampsia , 2008, Acta obstetricia et gynecologica Scandinavica.

[29]  H. Masuyama,et al.  Hypoadiponectinemia and circulating angiogenic factors in overweight patients complicated with pre-eclampsia. , 2006, American journal of obstetrics and gynecology.

[30]  C. Nappi,et al.  Maternal Serum and Umbilical Cord Blood Leptin Concentrations With Fetal Growth Restriction , 2003, Obstetrics and gynecology.